62484-31-5

Basic information

• Product Name: 2,4-Dichloro-7-methoxyquinazoline
• Synonyms: 2,4-Dichloro-7-methoxy-quinazoline;2,4-Dichloro-7-methoxyquizoline
• CAS NO: 62484-31-5
• Molecular Formula: C₉H₆Cl₂N₂O
• Molecular Weight: 229.06
• Product Categories: Heterocycles series
• Mol File: 62484-31-5.mol
• Article Data: 13

Chemical Properties

• Melting Point: 121-121.5 °C
• Boiling Point: 316 °C
• Flash Point: 145 °C
• Appearance: /
• Density: 1.450
• Vapor Pressure: 0.0475mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.26±0.30(Predicted)
• CAS DataBase Reference: 2,4-Dichloro-7-methoxyquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichloro-7-methoxyquinazoline(62484-31-5)
• EPA Substance Registry System: 2,4-Dichloro-7-methoxyquinazoline(62484-31-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 62484-31-5(Hazardous Substances Data)

Usage

Chemical Properties

White flocculent solids

Uses

2,4-Dichloro-7-methoxyquinazoline is a useful reactant for the preparation of 2, 4-?diaminoquinazoline derivatives which is being study for a potential to be a potent PAK4 inhibitors.

InChI:InChI=1/C9H6Cl2N2O/c1-14-5-2-3-6-7(4-5)12-9(11)13-8(6)10/h2-4H,1H3

Upstream product

• 32618-84-1 6-Methoxyquinazolin-2,4-dione 
• 409315-39-5 4-methoxy-2-ureido-benzoic acid amide 
• 38469-83-9 4-methoxy-2-nitro-benzonitrile 
• 38487-91-1 2-amino-p-anisamide 
• 4294-95-5 4-methoxyanthranilic acid 
• 857600-58-9 4-methoxy-2-ureido-benzoic acid 
• 62484-12-2 7-methoxyquinazoline-2,4(1H,3H)-dione 
• 62484-12-2 6-methoxy-quinazoline-2,4-diol 

Relevant articles and documents

HISTONE DEACETYLASE AND HISTONE METHYLTRANSFERASE INHIBITORS AND METHODS OF MAKING AND USE OF THE SAME

The compounds of formula (I) are dual inhibitors of the enzymes histone deacetylases (HDACs) and histone methyltransferase G9a, both of which are key posttranslational enzymes in cancer development.

SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS

The present invention relates to compounds of the following formula (I) and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.

Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors

Motivated by the pivotal role of CXCR4 as an HIV entry co-receptor, we herein report a de novo hit-to-lead effort on the identification of subnanomolar purine-based CXCR4 antagonists against HIV-1 infection. Compound 24, with an EC50 of 0.5 nM against HIV-1 entry into host cells and an IC50 of 16.4 nM for inhibition of radioligand stromal-derived factor-1α (SDF-1α) binding to CXCR4, was also found to be highly selective against closely related chemokine receptors. We rationalized that compound 24 complementarily interacted with the critical CXCR4 residues that are essential for binding to HIV-1 gp120 V3 loop and subsequent viral entry. Compound 24 showed a 130-fold increase in anti-HIV activity compared to that of the marketed CXCR4 antagonist, AMD3100 (Plerixafor), whereas both compounds exhibited similar potency in mobilization of CXCR4+/CD34+ stem cells at a high dose. Our study offers insight into the design of anti-HIV therapeutics devoid of major interference with SDF-1α function.